In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...
Read More
In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read More
In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for patients with advanced (stage 3 – 4) Hodgkin’s lymphoma (HL). This study concluded that this treatment is effective for these patients. Some background The most commonly used frontline chemotherapy regimen for advanced HL...
Read MoreIn a nutshell This trial will investigate the effects of different combinations of anti-cancer drugs in patients with pediatric Hodgkin lymphoma (HL). The main outcomes measured will be how fast a patient responds to therapy and also survival in general, and without cancer returning or getting worse. The trial is recruiting in Memphis, Tennessee,...
Read More
In a nutshell This study examined how safe and effective brentuximab vedotin (Adcedris) is when added to conventional treatments for relapsed and unresponsive Hodgkin lymphoma. This study concluded that this treatment is safe and effective when used as part of the treatment for Hodgkin lymphoma. Some background Standard treatment for...
Read More
In a nutshell This article reviews treatment strategies for patients with early-stage (stage 1 – 2) Hodgkin lymphoma (HL). Some background One of the main treatment goals for patients with HL is to improve long-term outcomes. However, many patients experience complications decades after initial treatment. These may include secondary cancer...
Read More
In a nutshell This study examined the safety and effectiveness of sintilimab in patients with relapsed or unresponsive Hodgkin lymphoma. This study concluded that sintilimab could be a new treatment option for these patients. Some background Hodgkin disease (HD) is a type of lymphoma. In patients who relapse or do not respond to first-line...
Read MoreIn a nutshell This study evaluated the long-term outcomes of radioimmunotherapy (RIT) in patients with follicular lymphoma (FL). This study concluded that RIT is a safe and effective long-term treatment option for these patients. Some background FL is the most common type of non-Hodgkin’s lymphoma. The current standard first-line treatment for...
Read More
In a nutshell This trial is examining the effectiveness of a new treatment combination for advanced Hodgkin’s lymphoma (HL). The main outcomes to be measured will be the number of patients who experience side effects and response to treatment. This study is being conducted in New York, New Jersey, and Ohio, the United States. The details The...
Read More
In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...
Read More
In a nutshell This study investigated complications associated with reduced-intensity EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) therapy for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was associated with high rates of drug delivery complications. Some background...
Read More
In a nutshell This study evaluated the outcomes of patients with mantle cell lymphoma (MCL) after front-line (primary) allogeneic stem cell transplantation (alloSCT). This study concluded that front-line alloSCT is effective in these patients. Some background Chemoimmunotherapy containing rituximab (Rituxan) is the typical front-line...
Read More
